First-Ever AHA/ACC/ADA/ASN Cardiovascular-Kidney-Metabolic (CKM) Syndrome Guideline (June 9, 2026): GLP-1 Therapies Embedded as Recommended Care
The American College of Cardiology, American Heart Association, American Diabetes Association, and American Society of Nephrology jointly published the first-ever clinical guideline for Cardiovascular-Kidney-Metabolic (CKM) Syndrome on June 9, 2026, in Circulation and JACC. The framework establishes a standardized CKM staging system (stages 0 to 4) to identify patients earlier, personalize therapy by absolute cardiovascular risk, and promote both prevention and regression of disease. GLP-1 receptor agonists are explicitly recommended in select patients with type 2 diabetes or obesity plus other cardiovascular risk factors, alongside SGLT2 inhibitors and kidney-protective therapies. The guideline embeds the GLP-1 class into multi-society standard of care for the first time and adds clinical-society weight to the SELECT, FLOW, and ESSENCE outcomes evidence base.